Physician profile
Dee G Mccrary
NPI 1942203278
$3,668.29
in general payments reported to CMS, 2019-2025
39 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $826 · 2021: $671 · 2022: $402 · 2023: $390 · 2024: $377 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,101.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $577.12 | 2019-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $440.07 | 2019-2023 | |
| Lilly USA, LLC | $353.68 | 2019-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $306.49 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amarin Pharma, INC. | $292.07 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $244.55 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $192.49 | 2019-2022 | |
| Astellas Pharma US INC | $176.63 | 2019-2025 | Veozah, Myrbetriq |
| Idorsia Pharmaceuticals US INC | $96.72 | 2022-2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.49 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $75.49 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $57.94 | 2019-2024 | |
| Abbvie INC. | $57.77 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.53 | 2022-2025 | |
| Axsome Therapeutics, INC. | $47.45 | 2023-2025 | Auvelity |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dee Mccrary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.